Neutrolis

Cambridge, United States

Neutrolis is a candidate-stage company advancing its first-in-class therapies that target Neutrophil Extracellular Traps (NETs).

$23.1M raised

Dec 2021

Series A

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Neutrolis raised?

Neutrolis has raised $23.1M in total funding. The most recent round was Series A. The last funding was announced in December 2021.

Who are Neutrolis's investors?

Neutrolis's investors include Morningside, Prefix Capital, PBJ Capital.

Where is Neutrolis headquartered?

Neutrolis is headquartered in Cambridge, United States.

What does Neutrolis do?

Neutrolis is a candidate-stage company advancing its first-in-class therapies that target Neutrophil Extracellular Traps (NETs).

What stage is Neutrolis at?

Neutrolis is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated December 3, 2021.

MLA

"Neutrolis — Funding & Investors." VCBacked, December 3, 2021, https://www.vcbacked.co/company/neutrolis. Accessed July 3, 2026.

APA

VCBacked. (2021). Neutrolis — Funding & Investors. Retrieved July 3, 2026, from https://www.vcbacked.co/company/neutrolis

Wikipedia (cite web)

{{cite web |title=Neutrolis — Funding & Investors |url=https://www.vcbacked.co/company/neutrolis |website=VCBacked |access-date=July 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated December 3, 2021.